TNFRSF10B and sarcoma: Strong anti-tumor activity has been demonstrated with the combination of anti-DR5 agonist IGM-8444 with the SMAC mimetic, birinapant, in preclinical models using a range of cell lines and PDX models, including sarcoma; for example, 7/9 animals were tumor-free in a model using the HT1080 cell line (Wang et al., 2022), which has also been used to model dedifferentiated chondrosarcoma (Pringle et al., 2022).